• Aucun résultat trouvé

Dimercaptosuccinic acid in combination with carbapenems against isogenic strains of Escherichia coli producing or not producing a metallo-β-lactamase in vitro and in murine peritonitis

N/A
N/A
Protected

Academic year: 2021

Partager "Dimercaptosuccinic acid in combination with carbapenems against isogenic strains of Escherichia coli producing or not producing a metallo-β-lactamase in vitro and in murine peritonitis"

Copied!
4
0
0

Texte intégral

(1)

Supplementary data

Table S1. Primers used for PCR amplification and cloning of carbapenemase genes.

Primer 5’ – 3’ sequence

NDM-1 EcoRV F GAT GAT GAT ATC TCA GCG CTG GCT GTT TTA CG

NDM-1 Bam R GAT GAT GGA TCC AAT CGC GCG ATG GCA GAT TG

VIM-2 EcoRV F GAT GAT GAT ATC AAA GTT ATG CCG CAC TCA CC

VIM-2 Bam R GAT GAT GGA TCC GCA TCT GCC TGC TAC TCA AC

IMP-1 EcoRV F GAT GAT GAT ATC AAA CGG ATG AAG GCA CGA AC

IMP-1 Bam R GAT GAT GGA TCC TAG TTG CTT GGT TTT GAT GG

OXA-48 EcorI F GAT GAT GAA TTC GAC GAG CAC AAT CGG CAT AG OXA-48 ScaI R GAT GAT AGT ACT CGC TAA CCA CTT CTA GGG AA KPC-3 F EcorI GAA TTC AAT TCC GCC ATC GTC AGT GCT CTA C KPC-3 R EcorI GAA TTC AAT TCA AGG GCG GCT GAA GGA ATA C

(2)

Table S2. MICs of imipenem, meropenem and ertapenem against susceptible strain E. coli CFT073 and isogenic derivatives expressing NDM-1, VIM-2, IMP-1, OXA-48 or KPC-3, with increasing concentrations of DMSA.

Strains Imipenem S ≤ 2 R > 4 mg/L Meropenem S ≤ 2 R > 8 mg/L Ertapenem S ≤ 0.5 R > 0.5 mg/L DMSA 0 DMSA 0.3 mM DMSA 1.5 mM DMSA 3 mM DMSA 6 mM DMSA 0 DMSA 0.3 mM DMSA 1.5 mM DMSA 3 mM DMSA 6 mM DMSA 0 DMSA 0.3 mM DMSA 1.5 mM DMSA 3 mM DMSA 6 mM CFT073 0.125 0.25 0.25 0.25 0.25 0.015 0.03 0.03 0.03 0.03 0.00375 0.015 0.0075 0.0075 0.015 CFT073-NDM-1 64 64 16 8 2 128 64 64 16 1 64 64 64 32 2 CFT073-VIM-2 8 4 4 2 2 4 4 2 0.5 0.125 4 2 1 0.5 0.06 CFT073-IMP-1 8 2 1 0.5 0.5 16 1 0.125 0.06 0.06 16 1 0.06 0.03 0.015 CFT073-OXA-48 1 2 2 2 2 0.125 0.25 0.25 0.25 0.25 0.125 0.25 0.25 0.25 0.25

(3)

CFT073-KPC-3

8 8 8 8 8 8 16 16 16 16 16 16 16 16 16

(4)

Table S3. Peak concentrations of DMSA obtained in plasma 30 min after a single dose in healthy adult human and in Swiss mice.

Species DMSA dosing

Mean concentration

(µM) (+/- SD)

Human (healthy adults)* 10 mg/kg (oral) 43 +/- 14 (n=6)

Mice (Swiss female) 100 mg/kg (intra-peritoneal) 6 +/- 4 (n=3)

Mice (Swiss female) 200 mg/kg (intra-peritoneal) 50 +/- 27 (n=3)

Mice (Swiss female) 400 mg/kg (intra-peritoneal) 182 +/- 21 (n=3)

*: data in human are from reference 37

** DMSA alone was not toxic in uninfected mice at dosages of 200 mg/kg q 4h and 400 mg/kg q 4h for

Figure

Table S1. Primers used for PCR amplification and cloning  of carbapenemase genes.
Table S2.  MICs of imipenem, meropenem and ertapenem against susceptible strain E. coli CFT073 and isogenic derivatives expressing NDM-1, VIM-2, IMP-1,  OXA-48 or KPC-3, with increasing concentrations of DMSA

Références

Documents relatifs

C’est ainsi avec un immense plaisir que le Conseil communal, appuyé par la Commission de la Culture, l’a désigné pour cette récompense», a notamment relevé Patrick Chapuis

Woodhams R, Matsunaga K, Iwabuchi K, Kan S, Hata H, Kuranami M, Watanabe M, Hayakawa K (2005) Diffusion-weighted imaging of malig- nant breast tumors: the usefulness of

Wohlgemuth ( 1957 ) and Büdel ( 1948 ) mentioned that high humidity favours the growth of microorganisms on the combs. In order to monitor the development of such growth, combs

In the target article, Prechtl & Powley (P & P) have persuasively concluded that B-neurons of the dorsal root ganglion represent the afferent divisions of the autonomic

In the present paper we study possible blow–ups and global exis- tence for a kinetic equation that describes swarm formations in the variable interacting rate case..

Dans cette étude rétrospective nous décrivons les caractéristiques épidémiologiques, cliniques, nosologiques et pronostiques du GBs et de ses sous-types cliniques dans une cohorte

L’accès à ce site Web et l’utilisation de son contenu sont assujettis aux conditions présentées dans le site LISEZ CES CONDITIONS ATTENTIVEMENT AVANT D’UTILISER CE SITE WEB..